PDS Biotech Shares Up 18% Premarket; Co Announced Thursday 12-month Survival Rate Of 87% With Pds0101 In Combination With Keytruda For Head And Neck Cancer Patients
Portfolio Pulse from Charles Gross
PDS Biotech shares rose 18% premarket after announcing a 12-month survival rate of 87% for head and neck cancer patients treated with PDS0101 in combination with Keytruda.
May 26, 2023 | 10:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PDS Biotech shares increased 18% premarket following the announcement of an 87% 12-month survival rate for head and neck cancer patients treated with PDS0101 and Keytruda.
The positive results of the PDS0101 and Keytruda combination treatment for head and neck cancer patients directly impact PDS Biotech's stock price. The 87% 12-month survival rate is a significant achievement, which is likely to boost investor confidence in the company's product pipeline and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100